LONDON, Nov. 14, 2016 /PRNewswire/ -- The global pyrogen testing market is projected to reach USD 1086.3 million by 2021 from USD 610.2 million in 2016, at a CAGR of 12.2% from 2016 to 2020. The major drivers for the market include increase in pharmaceutical and biological industries and increasing number of new drug launches. Over the years, the number of drug approvals in North American countries has increased from 2006 to 2015. In 2015, the FDA's Center for Drug Evaluation and Research (CDER) approved 45 novel drugs, approved as new molecular entities (NMEs) under New Drug Applications (NDAs) or as new therapeutic biologics under Biologics License Applications (BLAs) as compared to 22 novel drugs approved in 2006. The increasing number of drug approvals will boost the pyrogen testing market. According to OECD estimates, in 2011, the total number of biotechnology companies in the U.S. was 7,970, followed by Spain (3,025 biotechnology companies), and France (1,481 biotechnology companies). Owing to the rise in the number of biotechnology companies, biopharmaceutical production has increased globally. Pyrogen testing is carried out at all levels of pharmaceutical and biopharmaceutical manufacturing process to minimize the risk of product contamination. Growth in pharmaceutical and biotechnology industries will drive the growth of the pyrogen testing market. This report segments the global pyrogen testing market is segmented based on applications, products, tests, and geographies. In this report, the pyrogen testing market is categorized into three application segments-pharmaceuticals and biologicals manufacturing, medical devices manufacturing, and other applications such as water purification, food and beverages, cosmetics, and plastics and glass products. Based on products, the pyrogen testing market is segmented into kits and reagents, services, and instruments. In this report, the pyrogen testing market is categorized into three test segments- in vitro pyrogen test, LAL (Limulus amebocyte lysate) test, and rabbit test. The LAL test is further subsegmented in to chromogenic tests, turbidimetric tests, and gel clot tests.